{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P15692",
      "entity_text" : "VEGF",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:6442177",
      "entity_text" : "Everolimus",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Therapeutic agents targeting VEGF or mTOR signaling, such as Sorafenib XREF_BIBR, Pazopanib XREF_BIBR, Sunitinib XREF_BIBR, Bevacizumab XREF_BIBR, and Everolimus XREF_BIBR, have been successfully developed and clinically useful XREF_BIBR.",
  "reading_complete" : "2020-08-02T08:12:20Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T08:11:05Z",
  "trigger" : "signaling",
  "evidence" : [ "VEGF or mTOR signaling, such as Sorafenib  XREF_BIBR , Pazopanib  XREF_BIBR , Sunitinib  XREF_BIBR , Bevacizumab  XREF_BIBR , and Everolimus" ],
  "pmc_id" : "5399579",
  "score" : 0
}